Heart Failure Drugs Market to Reach USD 28.0 Billion by 2032

Heart Failure Drugs Market to Reach USD 28.0 Billion by 2032 as SGLT2 Adoption and Multi-Drug Therapy Reshape Revenue Growth

The Global Heart Failure Drugs Market was valued at approximately USD 18.4 billion in 2025 and is projected to reach approximately USD 28.0 billion by 2032, expanding at a CAGR of approximately 6.2% during 2026–2032.

The market is entering a period in which revenue growth is becoming less dependent on rising patient numbers alone and more closely linked to treatment intensity. Heart failure management increasingly combines several drug classes, including ARNI, SGLT2 inhibitors, beta blockers, mineralocorticoid receptor antagonists, ACE inhibitors or ARBs, and diuretics. As more diagnosed patients receive combination therapy, pharmaceutical value per treated patient is increasing.

The strongest commercial momentum is coming from newer therapies. SGLT2 inhibitors have expanded beyond diabetes into heart failure and chronic kidney disease, giving manufacturers access to a wider cardiovascular-renal-metabolic treatment population. Their role is particularly important in HFpEF, where the historical availability of disease-modifying therapies was comparatively limited.

At the same time, the market is becoming more complex from a revenue perspective. High prescription volumes in beta blockers, ACE inhibitors, ARBs, MRAs, and diuretics continue to support treatment demand, but generic availability limits their contribution to market value. In contrast, newer branded products account for a disproportionate share of pharmaceutical spending.

Among the major commercial franchises, Entresto, Jardiance, and Farxiga remain central to market competition. Novartis, Boehringer Ingelheim, Eli Lilly, and AstraZeneca therefore occupy important positions in the transition toward higher-value guideline-directed therapy. Bayer and Merck also participate through Verquvo, while generic manufacturers are gaining greater relevance as exclusivity expires across established cardiovascular products.

United States Remains the Largest Revenue Market

North America accounted for an estimated 37% of global Heart Failure Drugs Market revenue in 2025, equivalent to approximately USD 6.8 billion, with the United States contributing the majority.

Approximately 6.7–7.7 million U.S. adults are living with heart failure, creating one of the world's largest commercially treated populations. Heart failure contributed to around 452,573 U.S. deaths in 2023, while age-adjusted heart failure mortality increased by approximately 37% between 2010 and 2023.

The U.S. market benefits from intensive use of guideline-directed therapy and comparatively high pharmaceutical spending per patient. However, the beginning of generic competition in sacubitril/valsartan is changing the market's revenue structure. Future growth will increasingly depend on wider patient penetration, SGLT2 use, and combination therapy rather than continued expansion of individual blockbuster brands.

Germany Offers Therapy-Mix Upside Within a Large Existing Patient Pool

Germany's Heart Failure Drugs Market is estimated at approximately USD 1.25 billion in 2025 and is projected to reach around USD 1.81 billion by 2032.

A nationwide analysis covering approximately 74.3 million statutorily insured people identified around 2.2 million heart failure patients annually. Prescription patterns show high use of established therapies, while historical adoption of newer drug classes remained comparatively low.

Among newly diagnosed patients, approximately 59.3% received ACE inhibitors or ARBs, 55.9% beta blockers, and 44.3% diuretics, compared with only around 4.1% for ARNI and 3.3% for SGLT2 inhibitors during the observed period.

The commercial opportunity therefore lies in treatment migration rather than simple patient expansion. Greater penetration of newer therapies across an already large diagnosed population can increase pharmaceutical spending, although reference pricing, reimbursement controls, and generic competition will continue to limit price-led growth.

Japan Emerges as a Key HFpEF Revenue Opportunity

Japan's Heart Failure Drugs Market is estimated at approximately USD 1.05 billion in 2025 and is projected to reach approximately USD 1.65 billion by 2032.

Japan stands out because of the composition of its heart failure population. Clinical studies indicate that HFpEF accounts for approximately 44%–62% of hospitalized heart failure cases, creating a substantial treatment opportunity for therapies that can address preserved-ejection-fraction disease.

Prescription activity also demonstrates significant use of major cardiovascular brands. Fiscal 2024 claims-based estimates placed Entresto prescription value at around JPY 83 billion, Farxiga at approximately JPY 100 billion, and Jardiance at roughly JPY 82 billion across their approved indications.

The size of these prescription pools gives manufacturers a strong platform for expanding heart failure use, although Japan's regular national drug-price revisions will continue to restrain revenue growth per prescription.

Generic Entry Is Redefining the Market's Growth Model

One of the most important developments through 2032 will be the growing separation between prescription growth and revenue growth.

As patents expire and generic competition expands, treatment volumes can rise even while average revenue per prescription declines. This is already visible in older cardiovascular drug classes and is beginning to affect newer franchises.

The market is therefore shifting toward a model in which manufacturers must compete on therapy penetration, indication expansion, clinical positioning, and portfolio breadth rather than relying primarily on pricing.

HFpEF and Multi-Class Therapy Will Shape the Next Growth Cycle

HFrEF remains the largest revenue-generating heart failure segment because patients are commonly treated with multiple drug classes simultaneously. However, HFpEF is emerging as one of the most important areas for incremental market growth.

SGLT2 inhibitors have widened the commercially treated HFpEF population and reduced one of the major historical gaps in heart failure pharmacotherapy. Markets with high HFpEF prevalence, especially Japan and other aging healthcare systems, are likely to see some of the strongest treatment expansion.

The next phase of the Heart Failure Drugs Market will therefore be defined less by a single blockbuster product and more by the number of patients receiving multiple guideline-directed therapies over longer treatment periods.

Competitive Outlook

The competitive environment is increasingly divided between companies controlling high-value branded therapies and manufacturers competing in high-volume generic cardiovascular drugs.

Novartis remains strongly positioned through Entresto, while Boehringer Ingelheim and Eli Lilly compete through Jardiance and AstraZeneca through Farxiga. Bayer and Merck participate through Verquvo, while generic pharmaceutical companies are expanding their role across sacubitril/valsartan and established cardiovascular therapies.

Through 2032, the strongest commercial positions are likely to belong to companies that can maintain broad cardiovascular-renal-metabolic portfolios, expand treatment across multiple heart failure phenotypes, and offset pricing pressure through higher treatment penetration.